Starpharma has developed a pipeline of novel DEP® oncology products. Its clinical-stage assets, DEP® cabazitaxel, DEP® docetaxel, and DEP® irinotecan, are dendrimer versions of widely used chemotherapeutic drugs that have demonstrated improvements in efficacy and tolerability in Phase 2 clinical trials. Additionally, Starpharma has a preclinical pipeline of DEP® Antibody-Drug Conjugates (ADCs) and DEP® radiotheranostic products.

Starpharma has also established DEP® platform partnerships with leading global pharmaceutical companies.